After a four-year drought, Bavarian Nordic has finally had its first full year of profit. The company announced Wednesday that it had a full-year net profit of 25.9 Danish kroner ($3.72 million) and that it expects 1.1 billion kroner ($159 million) in revenue for 2015.
After a handful of large-scale monotherapy flops for cancer vaccines, many companies now think pairing them up as part of immunotherapy combos might be the way to go. And immuno-oncology pioneer Bristol-Myers Squibb just made a big bet that that's the case.
Bristol-Myers Squibb has swooped in with $60 million upfront to gain an option on Bavarian Nordic's Phase III therapeutic prostate cancer vaccine Prostvac, ready to shell out an additional $915 million-plus in milestones if it takes the next step to license and ultimately commercialize the therapy.
On Tuesday, Bavarian Nordic announced positive survival data from a Phase I combination study of its active prostate cancer immunotherapy candidate Prostvac and Bristol-Myers Squibb's Yervoy (ipilimumab), an immune checkpoint inhibitor.
Another Big Pharma player is joining the hustle toward an Ebola vaccine as the death toll surpasses 1,900 victims, eclipsing the total number of people who died from the disease in all previous outbreaks combined.
Canada has invited Danish company Bavarian Nordic--and only Bavarian Nordic--to bid for a tender to supply it with smallpox vaccines
Denmark's Bavarian Nordic may discover the dangers of putting all its eggs in one basket if the U.S. government does not order a smallpox vaccine by January.
The U.S. government will now allow individuals with HIV to receive an attenuated smallpox vaccine during an emergency, according to a release.
According to the U.K.'s The Telegraph, Bavarian Nordic's Prostvac prostate cancer vaccine has started a Phase III clinical trial in the U.K.
Sometimes, the sum of the parts is greater than the whole, and this can be true for cancer therapies as well. Researchers are hoping that combining Prostvac, the investigational therapeutic cancer...